243 filings
Page 5 of 13
8-K
m4uiqpta44woxr0a08dg
23 Sep 22
InMed Pharmaceuticals Reports Full Year Fiscal 2022 Financial Results and Provides Business Update
4:53pm
8-K
y8x3r48r
20 Sep 22
Regulation FD Disclosure
1:13pm
S-8 POS
1fmw1h7h7gs4
20 Sep 22
Registration of securities for employees (post-effective amendment)
9:18am
S-8 POS
pgmippg5qedxbqt
20 Sep 22
Registration of securities for employees (post-effective amendment)
9:16am
POS AM
dw21kd oq
20 Sep 22
Prospectus update (post-effective amendment)
9:15am
POS AM
vi7ztivj7rx 1q
20 Sep 22
Prospectus update (post-effective amendment)
9:14am
POS AM
ldbfpd
20 Sep 22
Prospectus update (post-effective amendment)
9:14am
POS AM
g48 602uaom
20 Sep 22
Prospectus update (post-effective amendment)
9:13am
POS AM
zulc36om
20 Sep 22
Prospectus update (post-effective amendment)
9:10am
8-K
yywslh5y
13 Sep 22
InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market
9:59pm
8-K
l75b436yhq
8 Sep 22
InMed Pharmaceuticals Provides Update on its Core Research and Development Programs and BayMedica Business
4:02pm
8-K
lv5l l6nylau0
26 Aug 22
InMed Announces Share Consolidation to Meet Nasdaq Listing Criteria
5:30pm
8-K
kbq84ko qz0rwvs
10 Aug 22
InMed Announces Changes to its Board of Directors
8:12pm
8-K
e7xyr
26 Jul 22
InMed Announces Update on Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa
1:32pm
8-K
pz7dhk4w
19 Jul 22
InMed Announces Appointment of Chief Operating Officer
7:43pm
8-K
sssn0
15 Jul 22
Departure of Directors or Certain Officers
8:28pm
424B3
wip9pmcjql1da2d1rkb
6 Jul 22
Prospectus supplement
2:43pm
EFFECT
wbwlj41 khmys6sh9p
30 Jun 22
Notice of effectiveness
12:15am
CORRESP
xq0zyr
27 Jun 22
Correspondence with SEC
12:00am